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We thank Doherty and colleagues for their thoughtful and pertinent response to our 
manuscript describing trends in immunodeficiency at antiretroviral therapy (ART) initiation 
in children in low, middle and high income countries.1 We agree that it is important to know 
more about the IeDEA sites included in the analysis in order to assess the extent to which 
they are representative of general public health facilities, and hence whether the finding of 
improvement in proportion of children with immunosuppression at ART initiation (albeit 
modest) is generalizable across these countries.
The IeDEA collaboration and the participating sites have therefore been described in 
dedicated profiles23 and a survey of the IeDEA sites providing HIV care for children has 
been published.4 The survey included 63 sites in Asia (10), Central Africa (4), East Africa 
(29), Southern Africa (10) and West Africa (10). Nearly 75% of sites were public 
government-run clinics, 65% were in urban settings and 57% provided pediatric care in 
combined adult-pediatric clinics.4 As pointed out by Doherty and colleagues, many sites 
received additional financial support from research grants (57%), the US PEPFAR 
programme (54%) or the Global Fund (24%).4 We cannot exclude that access to timely 
paediatric ART at non-IeDEA facilities may be even worse. However, all IeDEA sites 
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followed the relevant national ART guidelines and a strength of IeDEA data is that it is 
collected as part of routine care and not from dedicated research cohorts. We believe that the 
availability of individualized data through the IeDEA collaboration allowed a more nuanced 
picture of pediatric ART than analyses of program-level aggregate data, while preventing the 
ecological bias that may affect aggregate data analyses.5
We concur with Doherty and colleagues regarding the importance of advocacy for pediatric 
HIV as a neglected disease with an urgent need for better access to diagnostic tests and 
effective and safe pediatric-friendly drug formulations.6 The first barrier to early ART 
initiation is poor access to early infant diagnosis (EID) for which coverage remains low in 
many settings due to lack of virological diagnostic capacity, delivery services, and low social 
acceptability.78 Even in IeDEA sites, EID for infants was not universally available 
throughout the period of data collection, with the diagnosis of HIV being dependent on the 
presence of clinical symptoms. In the IeDEA site survey, access to certain drugs especially 
as part of fixed-dose combinations was limited in certain regions.4 Interestingly, Asian sites 
had poorer access to tenofovir and abacavir which may reflect more frequent eligibility for 
PEPFAR pricing in sub-Saharan Africa.4 We have also previously found limited access to 
second-line options for children, which may result in delays or lack of switching to second-
line therapy.910 While the dramatically increased coverage and effectiveness of prevention of 
mother to child transmission programmes is to be welcomed, there is a risk of even further 
neglect of treatment options for children as the market diminishes in size. In addition, the 
low priority and complexity of conducting research in children means that there is limited 
high quality data from randomized clinical trials to inform optimal pediatric treatment 
guidelines and drug choices. We strongly endorse the call for better drug options for 
children, especially for very young infants where treatment options are extremely limited 
and we know that there is substantial mortality and morbidity benefit in starting ART before 
3 months of age.11
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